Direxion Daily S&P Biotech Bear 3x Shares (LABD)
|Ex-Dividend Date||Mar 24, 2020|
|Day's Range||21.82 - 23.00|
|Inception Date||May 28, 2015|
The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.
|Mar 24, 2020||$0.9952||Mar 31, 2020|
|Dec 23, 2019||$0.278||Dec 31, 2019|
|Sep 24, 2019||$1.1708||Oct 1, 2019|
|Jun 25, 2019||$1.7478||Jul 2, 2019|
|Mar 19, 2019||$1.1286||Mar 26, 2019|
|Dec 27, 2018||$3.8268||Jan 4, 2019|
The biotech sector was one of the darlings amid the vaccine rally in 2020, but there's since been some bearishness, which is benefiting the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climbed...
Wall Street resumed its quarter-end decline in the face of rising yields. This has resulted in a spike in inverse or inverse leveraged ETFs.
September proved the historical trends to be true as Wall Street logged in the worst month of this year.
The broad market sell-off has resulted in a spike for inverse or inverse leveraged ETFs. These products either create a short position or a leveraged short position in the underlying index.
The S&P 500 Biotech index rose as much as 25% last year after falling as low as 8% during the apex of last year's sell-offs. Now, downward pressure is helping leveraged inverse funds like the Direxion D...
The COVID-19 pandemic put biotech in the spotlight as companies around the globe worked feverishly to create a vaccine. Once a tried-and-true vaccine is developed and subsequently incorporated as standa...
It's not just stocks that are made for shorting. Plenty of traders tap exchange-traded funds on the bearish side of things and do so for a variety of reasons.
The biotech and healthcare space has been on fire lately. The healthcare space is witnessing a Mergers and Acquisitions wave recently that has achieved an impressive $342 billion in new deal activity so...
The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.